Cardiff Oncology, Inc. 8-K

What Happened

• Cardiff Oncology, Inc. filed an 8-K on April 9, 2026 announcing executive appointments and related compensation. Mani Mohindru was named President and Chief Executive Officer (announcement dated April 9, 2026) after serving as Interim CEO. Josh Muntner was appointed Chief Financial Officer effective April 6, 2026, and Ajay Aggarwal, MD, MBA was appointed Chief Operating Officer effective April 27, 2026. The company also issued a press release on April 9, 2026 announcing these changes.

Key Details

• Mani Mohindru (President & CEO): base salary $655,000; a $100,000 bonus plus a 55% annual discretionary bonus. Stock awards: 200,000 incentive stock options granted Feb 17, 2026 (exercise price $1.56, exercisable May 17, 2026) and 600,000 incentive stock options granted Mar 31, 2026 (exercise price $1.62), vesting 4 years (25% after 12 months, then monthly over 36 months).
• Josh Muntner (CFO): base salary $475,000; 40% annual discretionary bonus. Inducement grant of 486,650 non‑qualified stock options (exercise price $1.58, the grant-date close), vesting over 4 years (25% after 12 months, then monthly).
• Ajay Aggarwal (COO): base salary $490,000; 40% annual discretionary bonus. He is expected to be granted 400,000 stock options (grant details not yet finalized).
• The filing states there are no arrangements or family relationships among these executives and other company officers or directors.

Why It Matters

• Leadership: Appointing a permanent CEO plus new CFO and COO is a material governance change that clarifies who will lead strategy and operations going forward.
• Compensation and incentives: Significant option grants and multi‑year vesting schedules align these executives’ pay with company stock performance but also create potential dilution—exercise prices cited ($1.56–$1.62) establish the strike levels for these awards.
• Timing and disclosure: The company publicly disclosed these appointments and compensation in an 8-K and press release, providing investors with concrete dates, salaries, bonus targets, and option quantities to assess executive incentives and potential share overhang.